π Pharmidex at OBN Science Social – Join Us! π¬
February 12, 2025
We’re excited to announce that Ash Alavijeh, our Head of Operations, will be attending the OBN Science Social in Stratford, London!
Today π Time: 18:00 - 20:00
π Location: Cancer Research Horizons, 2 Redman Place, London E20 1JQ
(https://lnkd.in/eQuhhzph)
Ash looks forward to meeting fellow attendees, engaging in insightful discussions, and exploring new opportunities for collaboration.
At Pharmidex, we are passionate about enhancing capabilities in drug discovery and development, and we’re always keen to connect with like-minded professionals.
If you're attending, don’t hesitate to say hello and have a chat! Looking forward to an evening of networking and innovation.
#Pharmidex #OBNScienceSocial #DrugDiscovery #Collaboration #Networking #PharmaInnovation
A big thank you to our interns from City St George’s, University of London and heir fantastic contribution to Pharmidex over the past few months. They have supported scientific projects across the business, developed valuable technical skills and gained hands-on experience within a CRO environment. Their contribution has extended beyond the laboratory, helping with our website, marketing materials, conference preparation and business development activities. Science drives success, but communicating that science effectively is just as important. Our interns have helped us do both. Thank you for your hard work, enthusiasm, and dedication. We wish you every success in the next stage of your careers.
On 18 June, our COO, Ash Alavijeh , will join an industry panel discussing: "What are the advantages and disadvantages of working with UK-based Discovery CROs?" The session will explore the value of UK CROs in supporting innovation, protecting IP, accessing scientific expertise and accelerating drug discovery programmes. π
18 June 2025 π Cambridge π Panel Session: 12:20–12:45 We look forward to connecting with colleagues, collaborators, and innovators from across the life sciences community.
This well-deserved appointment marks an important milestone in a remarkable career spanning more than 22 years at Pharmidex . Over the years, Dr Chishty has made a significant contribution to the growth of our DMPK capabilities, applying his extensive expertise in Drug Metabolism and Pharmacokinetics to support successful drug discovery and development programmes for clients worldwide. His scientific leadership, dedication and commitment to excellence have been instrumental in strengthening our services and supporting the continued success of Pharmidex . As we continue to grow and support innovative biopharmaceutical companies, we look forward to the impact Dr Chishty will make in this new role. Please join us in congratulating Dr Mansoor Chishty on this achievement and wishing him every success as Director of DMPK.
